Sanofi (SNY)
(Delayed Data from NSDQ)
$46.61 USD
-1.08 (-2.26%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $46.51 -0.10 (-0.21%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNY 46.61 -1.08(-2.26%)
Will SNY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNY
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal
Other News for SNY
Sanofi reportedly lining up banks for consumer products spinoff
Alto Neuroscience schizophrenia treatment shows good phase 1 results
IN BRIEF: Sanofi's rilzabrutinib meets phase-3 trial efficacy endpoint
Sanofi succeeds in late-stage trial for blood disorder candidate
Buy Rating Affirmed for Sanofi Amid Strong Growth Prospects and Undervalued Stock